02.19.2019 Issue 439

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

OptumRx Wants Pharma to Make Changes to Rebates

Friday, February 15

OptumRx is calling on pharmaceutical companies to deploy major changes toward rebates, according to a STAT report, but appears to be looking after its own bottom line.

Former Legislator Honors Dingell, His Health Politics

HCCI: Health Spending Rises Despite Little Change in Utilization

Article: Longitudinal Database Offers Number of Benefits

PolicyEd Announces New Video Series on Economic Fundamentals

ICER Releases Final New Evidence Update for Alirocumab

Kottler: Bolster Adherence to Increase Revenue, Keep Health Costs Under Control

NICE Provides First Advice on Patient Preference Study Design


Cardiovascular Medical Content Writer with AMCP Dossier and HEOR Knowledge

Senior Market Access Writer, Market Access Communications

Senior Consultant, Market Access Consulting

Associate Scientific Director/Director, Market Access Communications

Industry Spotlight


Conferences Webinars
18th Annual International Publication Planning Meeting
    February 20-21, San Diego, California

12th Annual Oncology Market Access Strategy Summit
    February 20-21, San Francisco, California

2019 Population Health Management Summit
    February 21-22, Miami, Florida

2019 Hospital Observation Patient Management Summit
    February 21-22, Miami, Florida

Clinical Statistics for Non-Statisticians
    February 27

Is the New Congress Ready to Lower Drug Costs?
    February 27

Amplifying the Patient Voice: Policy Solutions for Improving Patient-Reported Measures in Oncology Value-Based Payment Programs
    February 28

ICER: Payer Perspectives on the Use and Usage of ICER Reports
    February 28


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

HTA in Europe: Key Success Factors for Positive HTA Recommendations

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


 
Special Thanks to Our Partners:
               Truven            
          Evidera    HealthCore    University of FL   Xcenda
      OM1    Parexel    Jefferson    Dymaxium   Precision Xtract    
      Pharmerit    eMax Health    Sciformix   Evidence Partners    ICON
Share this newsletter on social media:

Email Twitter Facebook LinkedIn